XML 39 R27.htm IDEA: XBRL DOCUMENT

Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2018

Summarized information related to this collaboration is as follows:



	Three Months Ended March 31,
($ in millions)	2018
Alliance revenues (net of commercialization costs)	$	33

Materials and production⁽¹⁾	12
Marketing and administrative	7
Research and development	29

Receivables from AstraZeneca	31
Payables to AstraZeneca	783

⁽¹⁾Includes amortization of intangible assets.

Summarized information related to this collaboration is as follows:



	Three Months Ended March 31,
($ in millions)	2018		2017
Net product sales recorded by Merck	$	43	$	31
Merck’s profit share from sales in Bayer's marketing territories	25		53
Total sales	68		84

Materials and production⁽¹⁾	27		23
Marketing and administrative	8		7
Research and development	32		22

Receivables from Bayer	35
Payables to Bayer	—

⁽¹⁾Includes amortization of intangible assets.